Article thumbnail

Is there a clinical usefulness for radiolabeled somatostatin analogues beyond the consolidated role in NETs?

By Vincenzo Cuccurullo, Giuseppe Danilo Di Stasio, Maria Rosaria Prisco and Luigi Mansi


The somatostatin (SS) receptor scintigraphy (SRS), using octreotide radiolabelled with 111In (Ocreoscan©, OCT), is a consolidated diagnostic procedure in patients with neuroendocrine tumors (NET) because of an increased expression of somatostatin receptors (SS-R) on neoplastic cells. Uptake of SS analogues (SSA) can also be due to SS-R expression on nonmalignant cells when activated as lymphocytes, macrophages, fibroblasts, vascular cells. Because of this uptake, clinical indications can be found either in neoplasms not overexpressing SS-R, as nonsmall cell lung cancer, and in active benign diseases. Nevertheless, clinical application of SRS has not found clinical relevance yet. In this paper, we discuss the nononcologic fields of clinical interest in which SRS could play a clinical role such as diagnosis, prognosis, and therapy of benign and chronic diseases such as sarcoidosis, histiocytosis, rheumatoid arthritis, idiopathic pulmonary fibrosis, and Graves' ophthalmopathy

Topics: Autoimmune diseases; diagnostic imaging; Graves' ophthalmopathy; octreotide; osteomalacia; paraneoplastic syndromes; sarcoidosis; somatostatin, Medical physics. Medical radiology. Nuclear medicine, R895-920
Publisher: Wolters Kluwer Medknow Publications
Year: 2017
DOI identifier: 10.4103/ijri.IJRI_431_16
OAI identifier:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • (external link)
  • (external link)
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.